Real-Time European Filings API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Zur Rose Group AG

Earnings Release • Oct 16, 2025

1021_iss_2025-10-16_17396a2f-6a65-4b3e-92f5-3801d0d38ed1.html

Earnings Release

Open in Viewer

Opens in native device viewer

DocMorris AG / Key word(s): 9 Month figures

DocMorris accelerates sequential Rx growth and increases non-Rx revenue

16.10.2025 / 07:00 CET/CEST

Frauenfeld, 16 October 2025

Press release

DocMorris accelerates sequential Rx growth and increases non-Rx revenue

  • Total revenue rises by 9.5 per cent in the first nine months
  • Sequential Rx quarterly growth accelerates to 9.2 per cent in Q3
  • Non-Rx business in Germany grows in all areas; TeleClinic up over 140 per cent
  • Full roll-out of AI-based DocMorris health companion
  • Andrea Skersies appointed CCO and member of the Executive Board

CEO Walter Hess says: “Our continuous growth shows that we are on the right track with marketing efficiency in our core business and the scaling of innovative services. With the new AI-based DocMorris Health Companion, we are using artificial intelligence for millions of customers and patients and making it a tangible experience. We are also strengthening our position as Europe’s trusted health brand. David Masó becomes new Chief AI Health Officer, and with Chief Commercial Officer Andrea Skersies, we are expanding the Group Executive Board with an experienced e-commerce expert.”

CFO Daniel Wüest adds: “DocMorris has made an encouraging start to what is traditionally its strongest fourth quarter. The figures for the first nine months confirm our growth trajectory: we have significantly increased both revenue and our customer base and are on track to achieve our 2025 outlook. In the third quarter, the focus was on sustainable, profitable and future sales growth while improving profitability through efficiency gains and cost reductions. This will enable us to lay the foundation for achieving our EBITDA breakeven target in the course of 2026.”

Significant revenue growth in the first nine months

  • DocMorris increased its external revenue [1] by 9.5 per cent [2] to CHF 854.3 million in the first nine months 2025, despite the discontinuation of the Zur Rose brand in Germany at the end of 2024.
  • In the third quarter, sales increased by 8.1 per cent to CHF 282.3 million, despite the usual seasonal slowdown due to the summer holidays.
  • The Germany segment grew by 10.0 per cent in the first nine months, while revenue in the Europe segment increased by 2.7 per cent with a focus on profitability.
  • The number of active customers [3] increased from 10.3 million to 10.6 million in the first nine months and from 10.5 million to 10.6 million in the third quarter.

Sequential Rx growth continues to accelerate

  • External Rx revenue rose significantly by 37.9 per cent in the first nine months.
  • Sequential Rx growth continued to accelerate: from the second to the third quarter, Rx revenue increased by 9.2 per cent.

Revenue increase across all non-Rx areas

  • Non-Rx external revenue [4] increased by 4.3 per cent in the first nine months and also grew across all areas from the second to the third quarter.
  • TeleClinic increased its revenue by more than 140 per cent to over CHF 17 million in the first nine months and is increasingly becoming an important part of the German business.
  • TIME Magazine named TeleClinic one of the “World's Top HealthTech Companies 2025”.
  • Retail media and the marketplace achieved high double-digit growth.
  • All service platforms are making a disproportionately large contribution to profitability.

DocMorris health companion available to all app users

  • The AI-based DocMorris health companion has been available to all users of the DocMorris app since the beginning of October with the full rollout of the beta phase of the DocMorris Assistant.
  • DocMorris is also strengthening the strategic importance of the AI-based health companion in organisational terms and consolidates the associated activities relating to the digital health ecosystem under Executive Board member David Masó as the new Chief AI Health Officer (CAHO).

Streamlining management structures and using AI to increase efficiency

  • DocMorris is bundling all e-commerce activities in the Germany and Europe segments under Andrea Skersies as the new Chief Commercial Officer (CCO) and member of the Executive Board, while at the same time reducing one management level. Andrea Skersies has many years of management experience in online retail, including 13 years as Chief Marketing Officer (CMO) and member of the Executive Board at Zooplus and as CMO of an online pharmacy.
  • As part of this realignment, further management structures will be adjusted and the organisation streamlined in a targeted manner.
  • DocMorris is also reducing costs through the increased use of AI automation.

Outlook

  • Management confirms the revenue and earnings guidance for 2025 communicated on 10 April, as well as EBITDA breakeven in the course of 2026 and free cash flow breakeven in the course of 2027. The other medium-term targets remain unchanged.
Revenue, in CHF million (unaudited) 1.1.-30.9.2025 1.1.-30.9.2024 Change
DocMorris external revenue 854.3 795.8 7.4%
DocMorris external revenue in local currency 9.5%
DocMorris 809.4 744.7 8.7%
DocMorris in local currency 10.9%
Markets
Germany external revenue 806.2 748.0 7.8%
Germany external revenue in local currency 10.0%
Germany external revenue Rx 170.5 126.2 35.1%
Germany external revenue Rx in local currency 37.9%
Germany external revenue non-Rx 635.7 621.8 2.2%
Germany external revenue non-Rx in local currency 4.3.%
Germany 761.3 696.9 9.2%
Germany in local currency 11.4%
Europe 48.1 47.7 0.7%
Europe in local currency 2.7%
Revenue, in CHF million (unaudited) 1.7.-30.9.2025 1.7.-30.9.2024 Change
DocMorris external revenue 282.3 265.7 6.3%
DocMorris external revenue in local currency 8.1%
DocMorris 268.1 248.4 8.0%
DocMorris in local currency 9.8%
Markets
Germany external revenue 267.6 250.2 6.9%
Germany external revenue in local currency 8.8%
Germany external revenue Rx 60.9 48.1 26.4%
Germany external revenue Rx in local currency 28.8%
Germany external revenue non-Rx 206.8 202.1 2.3%
Germany external revenue non-Rx in local currency 4.1%
Germany 253.5 233.0 8.8%
Germany in local currency 10.7%
Europe 14.6 15.4 -5.0%
Europe in local currency -3.4%

Investors and analyst contact

Dr. Daniel Grigat, Head of Investor Relations & Sustainability

Email: [email protected], phone: +41 52 560 58 10

Media contact

Torben Bonnke, Director Communications

Email: [email protected], phone: +49 171 864 888 1

Agenda
20 January 2026 Sales 2025
19 March 2026 2025 Full-year results and outlook 2026 (conference call/webcast)
16 April 2026 Q1/2026 Trading update
12 May 2026 Annual General Meeting, Zurich
19 August 2026 2026 Half-year results (conference call/webcast)
15 October 2026 Q3/2026 Trading update

DocMorris

The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, telemedicine and marketplace with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands. TeleClinic is Germany’s largest telemedicine platform, connecting patients with more than 5,000 physicians. DocMorris operates leading marketplaces for health and personal care products in Southern Europe. With its broad range of products and services, DocMorris is pursuing its vision of becoming the leading digital health companion for everyone to manage their health in one click. Around 1,600 employees in Germany, the Netherlands, Spain, France, Portugal and Switzerland generated an external revenue of CHF 1,085 million serving more than10 million active customers in 2024. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning DocMorris AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of DocMorris AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. DocMorris AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

[1]  External revenue consists of the consolidated revenue of DocMorris plus online revenues of pharmacies supplied by DocMorris, less the consolidated revenue from supplying them.

[2]  All percentages are in local currency.

[3]  Customers supplied by DocMorris, either directly or through its partners.

[4]  Consisting of OTC business and services (TeleClinic, marketplace, retail media)

End of Media Release

Language: English
Company: DocMorris AG
Walzmühlestrasse 49
8500 Frauenfeld
Switzerland
ISIN: CH0042615283
Listed: SIX Swiss Exchange
EQS News ID: 2213728
End of News EQS News Service

2213728  16.10.2025 CET/CEST

Talk to a Data Expert

Have a question? We'll get back to you promptly.